HIV Vaccines: Basic Science
|
|
- Milo Barnett
- 5 years ago
- Views:
Transcription
1 Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV Vaccines: Basic Science Richard A. Koup, MD 6 th INTEREST Workshop May 9, 2012
2 Vaccine Research is not Linear Basic Science Clinical Results 1) Overview of clinical results that are driving the direction of HIV vaccine basic science 2) List unanswered questions that are the focus of current basic science efforts
3 Evidence for CTL Control of HIV Increased CTL activity in long-term non-progressors Rapid escape from CTL responses in acute and chronic infection Increase in SIV viremia with CD8+ T cell depletion Association between appearance of CTL and decline in viremia in acute infection
4 What Mediates Vaccine induced Protection? VIRUS TYPE OF VACCINE VACCINE INDUCED PROTECTION IMMUNE CONTROL Smallpox Live Antibodies, CTL CTL Rabies Killed virus Antibodies Antibodies, CD4, CTL Vaccine induced antibodies (neutralizing) most commonly protect against viral infections. Polio Live or killed virus Antibodies Antibodies Measles Live Antibodies; CTL Antibodies, CD4, CTL Mumps Live Antibodies Antibodies Rubella Live Antibodies Antibodies Little evidence that T cells actually mediate protection against viral challenge. Varicella zoster Live Antibodies; CTL Antibodies, CTL Influenza Protein Antibodies Antibodies, CD4, CTL Hepatitis A Killed virus Antibodies Antibodies, CD4, CTL Hepatitis B Protein Antibodies Antibodies, CD4, CTL However, once infected, T cells are clearly involved in mediating viral control. HPV VLP Antibodies CD4, CTL Hepatitis C CD4, CTL Cytomegalovirus CD4, CTL Epstein Barr virus CD4, CTL HSV types 1 and 2 CTL HIV 1 and HIV 2 CD4, CTL HHV 6 Antibodies, T cells
5 Therefore Efforts should be directed towards developing immunogens that stimulate neutralizing antibodies It has been difficult to induce neutralizing antibodies to HIV Variable loops Envelope is heavily glycosylated Shielding of neutralization domains Multiple clades of HIV with only limited crossneutralization Early vaccines generated binding, but not neutralizing, antibodies
6 Shifting Focus of HIV Vaccines gp160/gp120 subunits Poxvirus vector + protein rad5 gag/pol/nef DNA/rAd5 Env/gag/pol/nef Acquisition effect: % 31.5%? Antibody CD8 T cells Relative focus on vaccine effector mechanisms
7 RV144: The clinical result that is driving the focus of basic science
8 Efficacy (mitt) Objective: To carry out a correlates analysis to identify how the vaccine might work (generate hypotheses for further scientific studies)
9 Correlates Results on Six Assays Variable Relative risk P-value Q-value IgA Binding to Envelope IgG Avidity A244 gp ADCC AE.HIV-1 Infected CD4 Cells Tier 1 Neutralizing Antibodies IgG Binding to gp70-v1v CD4+ T Cell Intracellular Cytokines individual variables were significant: gp70 V1V2 inversely correlates with infection [q = 0.08] Estimated 43% reduction in infection rate Plasma IgA directly correlates with infection [q = 0.08] Estimated 54% increase in infection rate
10 Scaffolded gp70 V1V2 Protein V1 V2 alpha4, beta7 interaction motif V1V2 HIV-1 V1V2 His 6 gp70 Scaffold: Murine leukemia Virus gp70 Pinter A, et al. Vaccine 16:1903, 1998
11 Cumulative Infection Rates With V1V2 gp70 Scaffold Assay Low Medium High
12 Antibody Binding to Linear Peptides Proteins Loops 1.0 RV144 Vaccinees RV144 Placebos
13 Hypothesis: IgG Binding to gp70 V1V2 as a Surrogate for V2 Specific Neutralizing Antibodies V1V2 forms a beta sheet V1V2/glycan With a long CDR H3 loop V3/glycan Primary interaction with two glycans membrane proximal domain + lipid CD4 binding site gp120 inner domain gp120 outer domain McLellan et al, Nature, 2011 bridging sheet McLellan, Ofek, Zhou, Zhu, Kwong
14 PG 9/16 like Neutralizing Antibody Binding: C Strand of V1V2 Loop HIV infected RV144 DNA/Ad5
15 Conclusion: Correlates Analysis RV144 V1V2 binding antibodies correlated with protection This antibody binding maps to where broadly neutralizing PG 9/16 like antibodies bind The hypothesis these results generate is that the mechanism of protection in RV144 was mediated by PG 9/16 like (and potentially other) antibodies that were detected by the V1V2 scaffold assay, but not the neutralizing antibody panel What do we know about other neutralizing antibodies that could be targeted by a vaccine?
16 Other Neutralizing Antibodies V1V2/glycan V3/glycan Common Features: 1. Long CDR H3 loops Except CD4BS membrane proximal domain + lipid 2. Extensive somatic hypermutation Affinity maturation CD4 binding site gp120 inner domain gp120 outer domain bridging sheet McLellan, Ofek, Zhou, Zhu, Kwong
17 Neutralizing Activity of Patient Sera Chronic infection 110 HIV+ sera tested against panel of 20 viruses 100 JRFL - Infected > 15 years, stable CD4 - Plasma VL 10 20K - No ART Zhou and Kwong et al. Nature 2007 Percent Neutralization IgG concentration (ug/ml) Doria Rose/Connors et al. J Virology 2010;84:1631 Li/Mascola et al, Nat Med 2007;13:1032
18 Strategy for isolation of new mabs based on HIV epitope specific protein probes After 15 years of infection ~1.5% of B cells recognize gp140, but fewer than 1:2000 are specific for the CD4bs SA-PE X RSC3 (negative) SA-APC RSC3 (positive) Wu et al. Science 2010; 329:856
19 Broad Neutralization Against Tier 2 Isolates Panel of 190 Luciferase Reporter Viruses Expressing Diverse HIV-1 Envelope Glycoproteins VRC01 b12 gp160 protein distance Neighbor-Joining tree B D IC 50 < 1 μg/ml IC μg/ml IC 50 > 50 μg/ml HXB2 HXB2 C G Mike Seaman A IC 50 <50 µg 91% 41% IC 50 <1 µg 72% 17% Wu et al. Science 2010; 329:856
20 Mimicry of CD4 Receptor by Antibody VRC01 gp120 gp120 CD4 VRC01 heavy chain V-domain CD4 and VRC01 in highly similar positions Zhou et al. (2010) Science 329, 811
21 Other VRC01 like antibodies Different subjects Utilize similar IgG families IgG VH1 2*02 Extensive somatic hypermutation Affinity maturation Divergent primary aa sequences Similar mode of recognition Mimic CD4 Shared epitope target Wu et al, Science, 2011
22 Identification of VRC PG04 Sequences IAVI Donor 74 (VRC-PG04) VRC-PG04/VRC-PG04b 120,000 VH1-2 sequences Highly mutated > 5000 VRC-PG04 H identity (%) VRC03 VRC01, IGHV1-2*02 divergence (%) Wu et al, Science, 2011
23 Functional Analysis of VRC PG04 Like Heavy Chain Sequences Expressed heavy chain sequences VRC-PG04 H identity (%) % neutralization WT PG ug/ml H chain paired with PG04 light IGHV1-2*02 divergence (%) neutralization no neutralization Demonstration that particular heavy chains can neutralize HIV-1 Design immunogens that drive the antibody response along this pathway Wu et al, Science, 2011
24 Summary: Neutralizing Antibodies There are several targets for broadly neutralizing antibodies on HIV 1 Env Most share features of long CDR H3 loops and extensive somatic hypermutation New cloning and direct sequencing methods are streamlining the NA discovery effort Demonstrating somatic hypermutation pathways to guide immunogen design How can we induce long CDRH3s and extensive somatic hypermutation through vaccination?
25 Follicular T Helper Cells: T FH Proliferation of B cells Induction of AID (activation induced deaminase) Leads to somatic hypermutation At what stage of B cell development is the CDRH3 length determined? Nutt and Tarlinton Nature Immunology 12: , 2011
26 Heavy chain Igs are rearranged by the pre B cell stage, in the bone marrow HCDR3 Length Long HCDR3s are present in naïve B cells, before encounter with antigen QIAGEN
27 Don t Forget the Other End of the Antibody Can the interactions of the Fc domain with cell and complement receptors contribute to vaccine-induced Ab-mediated protection?
28 AIDS Vaccine Science A Work in Progress Michelangelo s Unfinished Atlas In the battle between antibody and T cell vaccines, antibodies appear to have won Unanswered questions: 1. Do V2-specific antibodies mediate protection, or are they just a surrogate? 2. If they mediate protection, what is the mechanism: Neutralizing vs nonneutralizing? 3. Can other targets of neutralizing antibodies be exploited in vaccine design? MPER, CD4BS 4. Do we need to induce antibodies with long CDRH3 loops and extensive hypermutation? 5. If so, how do we do that? 6. What is the mechanism of protection by nonneutralizing antibodies? 7. Is the Fc tail involved? 8. How do we induce the correct Fc modifications through vaccination?
29 Conclusions Correlates of risk have been determined for RV144 V1V2 binding antibodies This correlate raises the hypothesis that V2 directed antibodies mediated the protection in that trial This knowledge is leading to new areas of scientific discovery in HIV vaccine science Other neutralizing antibody targets are known Ab structure and sequence analysis is being applied to guide immunogen design Future trials (HVTN505) will benefit from the experience gained in evaluating RV144
30 Results from HIV prevention trials Study Length Effect size of Study (CI) HIV Vaccine (Thai RV144) 3.5 y 31% (1, 51) 1% TDF gel (Caprisa, Karim et al.) 2.5 y 39% (6, 60) TDF/FTC PrEP (iprex, Grant et al 2010) 1.2 y 44% (15, 63) 12 mo effect Circumcision (Orange Farm, Rakai, Kisumu) 57% (42, 68) 0% % Efficacy An HIV vaccine should be considered a component of a comprehensive approach to HIV prevention Prof. Glenda Gray, HVTN Conference, Nov 2010 Padian NS, et al. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010, 24:
31 Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Vaccine Research Center Gary Nabel Peter Kwong John Mascola Daniel Douek Robert Seder Immunology Core Bob Bailer & staff Laurie Lamoreaux Collaborators Nelson Michael Jerome Kim Larry Corey Julie McElrath Flow Cytometry Core Mario Roederer & staff Clinical Trials Core Barney Graham Mary Enama & staff Brenda Larkin & staff Contractors Vical GenVec Community Advisory Board Vaccine trial volunteers!
32 Acknowledgements
33 Acknowledgements University of Washington And 16,402 Thai men and women who participated in the trial
HIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationFrom Antibody to Vaccine a Tale of Structural Biology and Epitope Scaffolds
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services From Antibody to Vaccine a Tale
More informationNIAID Vaccine Research Center: A Mission to Prevent HIV Infection
NIAID Vaccine Research Center: A Mission to Prevent HIV Infection AIDS Vaccine Awareness Day 20 year anniversary May 18, 2017 Barney S. Graham, MD, PhD Deputy Director Origins of the VRC 1997 1998
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers accine Research Center ational nstitute of Allergy and nfectious Diseases ational nstitutes of Health H and Challenges of accine Development Richard A. Koup, MD What Mediates accine-induced
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More informationIsolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient
Isolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient Amanda Fabra García, Carolina Beltrán Pavez, Alberto Merino Mansilla, Cristina Xufré, Isabel
More informationThe Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
More informationHIV: RV 144 prime boost HIV vaccine efficacy study
HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research
More informationProgress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe
More informationIdentification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing
More informationAlternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
More informationShould There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy
More informationUniversal Influenza Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Universal Influenza Vaccine Development 2016 Global Vaccine and Immunization
More informationProfessor Andrew McMichael
BHIVA AUTUMN CONFERENCE 2011 Including CHIVA Parallel Sessions Professor Andrew McMichael University of Oxford 17 18 November 2011, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationWhy are validated immunogenicity assays important for HIV vaccine development?
Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationOverview of the Joint HVTN/HPTN Research Portfolio. Theresa Gamble, PhD HPTN LOC May 15, 2018
Overview of the Joint HVTN/HPTN Research Portfolio Theresa Gamble, PhD HPTN LOC May 15, 2018 1 Joint HVTN/HPTN mab Portfolio HVTN 130/HPTN 089 HVTN 703/HPTN 081 HVTN 704/HPTN 084 AMP (VRC01) HVTN 127/HPTN
More informationHIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Adaptive Immunity Innate immunity: (Antigen - nonspecific) defense
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationLong-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018
Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018 Global HIV Statistics 2017 People living with HIV in 2016 New HIV infections
More informationIdentification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist
Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1
More informationEmerging Viruses. Part IIb Follow Up from Part I Vaccines and Inhibitors
Emerging Viruses Part IIb Follow Up from Part I Vaccines and Inhibitors Cellular Responses to Viral Invasion: Restriction Factors Cells fight viral infection using a series of restriction factors Restriction
More informationAdvancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
More informationAdaptive Immunity: Humoral Immune Responses
MICR2209 Adaptive Immunity: Humoral Immune Responses Dr Allison Imrie 1 Synopsis: In this lecture we will review the different mechanisms which constitute the humoral immune response, and examine the antibody
More informationEMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)
AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,
More informationImmunobiology 7. The Humoral Immune Response
Janeway Murphy Travers Walport Immunobiology 7 Chapter 9 The Humoral Immune Response Copyright Garland Science 2008 Tim Worbs Institute of Immunology Hannover Medical School 1 The course of a typical antibody
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationGene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
More informationALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144
ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen Results of the Thai HIV Vaccine Trial, RV144 SupachaiRerks-Ngarm, PunneePittisutthithum, SorachaiNitayaphan, JaranitKaewkungwal,
More informationSupplementary information. Early development of broad neutralizing antibodies in HIV-1 infected infants
Supplementary information Early development of broad neutralizing antibodies in HIV-1 infected infants Leslie Goo, Vrasha Chohan, Ruth Nduati, Julie Overbaugh Supplementary Figure 1. Neutralization profile
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationHelminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii. Ringworm fungus HIV Influenza
Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii Ringworm fungus HIV Influenza Candida Staph aureus Mycobacterium tuberculosis Listeria Salmonella Streptococcus Levels
More informationSupplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood
Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood tree illustrating CRF01_AE gp120 protein sequence relationships between 107 Envs sampled in the RV144 trial
More informationVirus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies
Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Michael Seaman, Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Harvard Medical School J. Virol.
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationCELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.
!! www.clutchprep.com CONCEPT: OVERVIEW OF HOST DEFENSES The human body contains three lines of against infectious agents (pathogens) 1. Mechanical and chemical boundaries (part of the innate immune system)
More informationEngineering an in vitro human immune system for rapid vaccine evaluation
Engineering an in vitro human immune system for rapid vaccine evaluation William Warren, Ph.D. VaxDesign Corporation Orlando, FL 32826 wwarren@vaxdesign.com www.vaxdesign.com 1 MIMIC Technology Overview
More informationLynn Morris. "Plan B"- bnabs for HIV prevention
"Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More information3. Lymphocyte proliferation (fig. 15.4): Clones of responder cells and memory cells are derived from B cells and T cells.
Chapter 15 Adaptive, Specific Immunity and Immunization* *Lecture notes are to be used as a study guide only and do not represent the comprehensive information you will need to know for the exams. Specific
More informationAdaptive Immune System
Short Course on Immunology Adaptive Immune System Bhargavi Duvvuri Ph.D IIIrd Year (Immunology) bhargavi@yorku.ca Supervisor Dr.Gillian E Wu Professor, School of Kinesiology and Health Sciences York University,
More informationTrials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand
More informationMay HIV Vaccines: The Basics
May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the
More informationWhat is the place of the monoclonal antibodies in the clinic?
What is the place of the monoclonal antibodies in the clinic? Dr Julià Blanco 2018/04/26 DISCLOSURE AlbaJuna Therapeutics, S.L. ANTIBODIES IN HIV INFECTION. ANTIVIRAL (NEUTRALIZING) ACTIVITY env THE BROADLY
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationHVTN Laboratory Program: Immunogenicity and Research Assays
HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,
More informationHigher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,
More informationAntigen Receptor Structures October 14, Ram Savan
Antigen Receptor Structures October 14, 2016 Ram Savan savanram@uw.edu 441 Lecture #8 Slide 1 of 28 Three lectures on antigen receptors Part 1 (Today): Structural features of the BCR and TCR Janeway Chapter
More informationCrystal structure of the neutralizing antibody HK20 in complex with its gp41 antigen
Crystal structure of the neutralizing antibody HK20 in complex with its gp41 antigen David Lutje Hulsik Unit for Virus Host Cell Interaction UMI 3265 University Joseph Fourier-EMBL-CNRS, Grenoble Env catalyzed
More informationWhite Blood Cells (WBCs)
YOUR ACTIVE IMMUNE DEFENSES 1 ADAPTIVE IMMUNE RESPONSE 2! Innate Immunity - invariant (generalized) - early, limited specificity - the first line of defense 1. Barriers - skin, tears 2. Phagocytes - neutrophils,
More information2005 LANDES BIOSCIENCE. DO NOT DISTRIBUTE.
[Human Vaccines 1:2, 45-60; March/April 2005]; 2005 Landes Bioscience Review Role of Neutralizing Antibodies in Protective Immunity Against HIV Indresh K. Srivastava* Jeffrey B. Ulmer Susan W. Barnett
More informationThe challenge of an HIV vaccine from the antibody perspective. Dennis Burton The Scripps Research Institute
The challenge of an HIV vaccine from the antibody perspective Dennis Burton The Scripps Research Institute AIDS Pandemic Nov 2005 North America 1.2 million [650 000 1.8 million] Caribbean 300 000 [200
More informationTools to therapeutically harness the human antibody response
Tools to therapeutically harness the human antibody response Patrick C. Wilson 1,2 and Sarah F. Andrews 1 Abstract The natural human antibody response is a rich source of highly specific, neutralizing
More informationالحترمونا من خري الدعاء
الحترمونا من خري الدعاء Instructions for candidates The examination consists of 30 multiple choice questions, each divided into 5 different parts. Each part contains a statement which could be true or
More informationStructural Insights into HIV-1 Neutralization by Broadly Neutralizing Antibodies PG9 and PG16
Structural Insights into HIV-1 Neutralization by Broadly Neutralizing Antibodies PG9 and PG16 Robert Pejchal, Laura M. Walker, Robyn L. Stanfield, Wayne C. Koff, Sanjay K. Phogat, Pascal Poignard, Dennis
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationThird line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!
Topic 8 Specific Immunity (adaptive) (18) Topics - 3 rd Line of Defense - B cells - T cells - Specific Immunities 1 3 rd Line = Prophylaxis via Immunization! (a) A painting of Edward Jenner depicts a cow
More informationThe Rational Design of an AIDS Vaccine
Leading Edge Essay The Rational Design of an AIDS Vaccine Daniel C. Douek, 1 Peter D. Kwong, 1 and Gary J. Nabel 1, * 1 Vaccine Research Center, NIAID, National Institutes of Health, Room 4502, Building
More informationAdaptive Immunity: Specific Defenses of the Host
17 Adaptive Immunity: Specific Defenses of the Host SLOs Differentiate between innate and adaptive immunity, and humoral and cellular immunity. Define antigen, epitope, and hapten. Explain the function
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationThe History of HIV Vaccine Development
The History of HIV Vaccine Development a short story on 30 years of research å Dr. Jill Gilmour International AIDS Vaccine Initiative Barcelona, 6 October 2013 IAVI is a product-development partnership
More informationThere are 2 major lines of defense: Non-specific (Innate Immunity) and. Specific. (Adaptive Immunity) Photo of macrophage cell
There are 2 major lines of defense: Non-specific (Innate Immunity) and Specific (Adaptive Immunity) Photo of macrophage cell Development of the Immune System ery pl neu mφ nk CD8 + CTL CD4 + thy TH1 mye
More informationLines of Defense. Immunology, Immune Response, and Immunological Testing. Immunology Terminology
Immunology, Immune Response, and Immunological Testing Lines of Defense If the First and Second lines of defense fail, then the Third line of defense is activated. B and T lymphocytes undergo a selective
More informationHIV cure: current status and implications for the future
HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence
More informationImmunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008
Immunity to Viruses Patricia Fitzgerald-Bocarsly September 25, 2008 The Immune System Deals with a Huge Range of Pathogens Roitt, 2003 Immune Responses to Viruses Viruses are dependent on the host cell
More informationall of the above the ability to impart long term memory adaptive immunity all of the above bone marrow none of the above
1. (3 points) Immediately after a pathogen enters the body, it faces the cells and soluble proteins of the innate immune system. Which of the following are characteristics of innate immunity? a. inflammation
More informationAcquired Immunity 2. - Vaccines & Immunological Memory - Wataru Ise. WPI Immunology Frontier Research Center (IFReC) Osaka University.
Acquired Immunity 2 - Vaccines & Immunological Memory - Wataru Ise WPI Immunology Frontier Research Center (IFReC) Osaka University Outline 1. What is vaccine (vaccination)? 2. What is immunological memory?
More informationResearch Online. Edith Cowan University. Constantinos K. Wibmer. Jinal N. Bhiman. Elin S. Gray Edith Cowan University,
Edith Cowan University Research Online ECU Publications 2013 2013 Viral Escape From HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition Of Multiple
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationThe Adaptive Immune Response. B-cells
The Adaptive Immune Response B-cells The innate immune system provides immediate protection. The adaptive response takes time to develop and is antigen specific. Activation of B and T lymphocytes Naive
More informationBispecific Fusion Antibodies. Exhibit 100% Breadth and Picomolar Potency. Craig Pace, PhD
The Aaron Diamond AIDS Research Center Affiliate of The Rockefeller University Bispecific Fusion Antibodies PG9 Ibalizumab & VRC Ibalizumab Exhibit % Breadth and Picomolar Potency Craig Pace, PhD AIDS
More informationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target Laura M. Walker, 1 * Sanjay K. Phogat, 2 * Po-Ying Chan-Hui, 3 Denise Wagner, 2 Pham Phung, 4 Julie L. Goss,
More informationPreferential induction of cross-group influenza A hemagglutinin stem specific memory B cells after H7N9 immunization in humans
INFECTIOUS DISEASE Preferential induction of cross-group influenza A hemagglutinin stem specific memory B cells after immunization in humans Sarah F. Andrews, 1 * M. Gordon Joyce, 1 Michael J. Chambers,
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationChapter 1. Chapter 1 Concepts. MCMP422 Immunology and Biologics Immunology is important personally and professionally!
MCMP422 Immunology and Biologics Immunology is important personally and professionally! Learn the language - use the glossary and index RNR - Reading, Note taking, Reviewing All materials in Chapters 1-3
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationPLAN. Réponses B thymodépendantes et thymoindépendantes. B cell development and classification. B cell activation. Thymodependent B(2) cell response
Réponses B thymodépendantes et thymoindépendantes PLAN B cell development and classification B cell activation Thymodependent B(2) cell response BMC 423 (IF) - 2007 Antonino Nicoletti Thymo-independent
More informationAntigen-Independent B-Cell Development Bone Marrow
Antigen-Independent B-Cell Development Bone Marrow 1. DNA rearrangements establish the primary repertoire, creating diversity 2. Allelic exclusion ensures that each clone expresses a single antibody on
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationDevelopment of prophylactic vaccines against HIV-1
Schiffner et al. Retrovirology 2013, 10:72 REVIEW Open Access Development of prophylactic vaccines against HIV-1 Torben Schiffner 1, Quentin J Sattentau 1* and Lucy Dorrell 2,3 Abstract The focus of most
More informationChapter 11. B cell generation, Activation, and Differentiation. Pro-B cells. - B cells mature in the bone marrow.
Chapter B cell generation, Activation, and Differentiation - B cells mature in the bone marrow. - B cells proceed through a number of distinct maturational stages: ) Pro-B cell ) Pre-B cell ) Immature
More informationClinical Evaluation the HIV-1 CD4 Binding Site-Specific Monoclonal Antibody VRC01. Barney S. Graham, MD, PhD August 8, 2014
Clinical Evaluation the HIV-1 CD4 Binding Site-Specific Monoclonal Antibody VRC01 Barney S. Graham, MD, PhD August 8, 2014 An Integrated Approach to HIV Vaccine Development MPER CD4bs V1V2 glycan V3 glycan
More informationChapter 11. B cell generation, Activation, and Differentiation. Pro-B cells. - B cells mature in the bone marrow.
Chapter B cell generation, Activation, and Differentiation - B cells mature in the bone marrow. - B cells proceed through a number of distinct maturational stages: ) Pro-B cell ) Pre-B cell ) Immature
More informationChallenges in Designing HIV Env Immunogens for Developing a Vaccine
b514_chapter-13.qxd 12/4/2007 3:39 PM Page 327 Chapter 13 Challenges in Designing HIV Env Immunogens for Developing a Vaccine Indresh K. Srivastava* and R. Holland Cheng Summary HIV continues to be a major
More informationAre we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
More informationκ λ Antigen-Independent B-Cell Development Bone Marrow Ordered Rearrangement of Ig Genes During B-Cell Development in the Bone Marrow
Antigen-Independent B-Cell Development Bone Marrow 1. DNA rearrangements establish the primary repertoire, creating diversity 2. Allelic exclusion ensures that each clone expresses a single antibody on
More informationTrends in vaccinology
Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March
More informationReceived 28 January 2011/Accepted 24 February 2011
JOURNAL OF VIROLOGY, May 2011, p. 4828 4840 Vol. 85, No. 10 0022-538X/11/$12.00 doi:10.1128/jvi.00198-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. The Neutralization Breadth
More informationVirus. Landmarks in Virology. Introduction to Virology. Landmarks in Virology. Definitions. Definitions. Latin for slimy liquid or poison
Landmarks in Virology Introduction to Virology Scott M. Hammer, M.D. Introduction of concept of filterable agents for plant pathogens (Mayer, Ivanofsky, Beijerinck in late 1880 s) First filterable agent
More informationBoosts Following Priming with gp120 DNA
Neutralizing Antibody Responses Induced with V3-scaffold Protein Boosts Following Priming with gp120 DNA Susan Zolla-Pazner NYU School of Medicine Problems with Whole Env Immunogens Poor induction of Abs
More informationUniversity of Massachusetts Medical School Matthew R. Costa University of Massachusetts Medical School
University of Massachusetts Medical School escholarship@umms GSBS Dissertations and Theses Graduate School of Biomedical Sciences 10-12-2016 FC Receptor-Mediated Activities of Env-Specific Monoclonal Antibodies
More informationTest Bank for Basic Immunology Functions and Disorders of the Immune System 4th Edition by Abbas
Test Bank for Basic Immunology Functions and Disorders of the Immune System 4th Edition by Abbas Chapter 04: Antigen Recognition in the Adaptive Immune System Test Bank MULTIPLE CHOICE 1. Most T lymphocytes
More informationLecture 11. Immunology and disease: parasite antigenic diversity
Lecture 11 Immunology and disease: parasite antigenic diversity RNAi interference video and tutorial (you are responsible for this material, so check it out.) http://www.pbs.org/wgbh/nova/sciencenow/3210/02.html
More informationIncreasing Neutralisation resistance in HIV-1 Clade C over the course of the southern African Epidemic. Cecilia Rademeyer 26 October 2014
Increasing Neutralisation resistance in HIV-1 Clade C over the course of the southern African Epidemic. Cecilia Rademeyer 26 October 2014 HIV-1 Transmission and Antigenic Drift Individual Selection Transmission
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationShiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School
CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation
More information